$5.61+0.05 (+0.90%)
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
Abeona Therapeutics Inc. in the Healthcare sector is trading at $5.61 with a market capitalization of $327M. Wall Street consensus targets $19.71 (7 analysts), implying a +251.4% move over the next 12 months. The stock is currently 26% below its 52-week high of $7.54, remaining 7.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $8.72Mβ | $5.42M | $0β | $400,000 | $0 |
| Gross Profit | $6.02Mβ | $2.58Mβ | -$488,000β | $300,000 | $0 |
| Operating Income | -$23.03Mβ | -$22.91Mβ | -$24.02Mβ | -$22.79Mβ | -$19.73M |
| Net Income | -$17.07Mβ | -$20.46Mβ | -$5.16Mβ | $108.83Mβ | -$12.03M |
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients wi...
Over the last 7 days, the United States market has experienced a 3.3% drop, yet it remains up by 22% over the past year with earnings expected to grow by 17% annually. In this context, identifying growth companies with high insider ownership can be particularly appealing as it often indicates strong confidence from those closest to the business in its future potential.
Over the last 7 days, the United States market has experienced a 3.3% decline, yet it remains up by 22% over the past year with earnings anticipated to grow by 17% annually in the coming years. In this context, growth companies with substantial insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business's operations and potential.
Over the last 7 days, the United States market has dropped by 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this context of fluctuating performance and anticipated growth, stocks with high insider ownership can be appealing as they often signal confidence from those closest to the company's operations and potential for substantial earnings growth.
Over the last 7 days, the United States market has dropped 2.5%, yet it remains up by 23% over the past year, with earnings projected to grow by 17% annually in the coming years. In this fluctuating environment, identifying growth companies with high insider ownership can be particularly appealing as these firms often demonstrate strong potential and a vested interest from those who know them best.
In the past week, the United States market has seen a 1.6% increase and is up an impressive 28% over the last year, with earnings projected to grow by 17% annually in the coming years. In this thriving environment, identifying growth companies with significant insider ownership can be crucial as it often indicates confidence from those closest to the business and aligns their interests with shareholders.